The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

A doctor has issued a warning about a less documented side effect of Ozempic that can apparently have a long-term health ...

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of ... active ingredient in diabetes drug Ozempic and weight-loss drug Wegovy ...